1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273-5.
2. Sugano K, Tack J, Kuipers EJ, Graham DY. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.  DOI:10.1136/gutjnl-2015-309252
3. Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI:10.1136/gutjnl-2016-312288
4. Ивашкин В.Т., Маев И.В., Лапина Т.Л., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Росийский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70 [Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70  (in Russian)]. DOI:10.22416/1382-4376-2018-28-1-55-70
5. Park JY, Herrero R. Recent progress in gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2021;50-51:101733.  DOI:10.1016/j.bpg.2021.101733
6. Бордин Д.С., Войнован И.Н., Эмбутниекс Ю.В., и др. Европейский регистр Helicobacter pylori (Hp-EuReg) как инструмент для оценки и улучшения клинической практики в Москве. Терапевтический архив. 2020;92(2):12-8 [Bordin DS, Voynovan IN, Embutnieks YuV, et al. European registry on Helicobacter pylori management  (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):12-8  (in Russian)]. DOI:10.26442/00403660.2020.02.000567
7. Reshetnyak VI, Burmistrov AI, Maev IV. Helicobacter pylori: Commensal, symbiont or pathogen? World J Gastroenterol. 2021;27(7):545-60. DOI:10.3748/wjg.v27.i7.545
8. Lansdorp-Vogelaar I, Meester RGS, Laszkowska M, et al. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol. 2021;50-51:101735. DOI:10.1016/j.bpg.2021.101735
9. Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 2021;22(6):729-41.  DOI:10.1080/14656566.2020.1845649
10. Tacconelli E, Carrara E, Savoldi A, et al. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-27.  DOI:10.1016/S1473-3099(17)30753-3
11. Moghadam MT, Chegini Z, Norouzi A, et al. Three-Decade Failure to the Eradication of Refractory Helicobacter pylori Infection and Recent Efforts to Eradicate the Infection. Curr Pharm Biotechnol. 2021;22(7):945-59. DOI:10.2174/1389201021666200807110849
12. Oh JH, Kwon JG, Jung HK, et al. Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil. 2020;26(1):29-50. DOI:10.5056/jnm19209
13. Gravina AG, Priadko K, Ciamarra P, et al. Extra-Gastric Manifestations of Helicobacter pylori Infection. J Clin Med. 2020;9(12):3887. DOI:10.3390/jcm9123887
14. Zuo ZT, Ma Y, Sun Y, et al. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma. Int Arch Allergy Immunol.  2021;182(1):53-64. DOI:10.1159/000508330
15. Marshall B. The future of Helicobacter pylori eradication: a personal perspective. Aliment Pharmacol Ther. 1997;11(Suppl. 1):109-15. DOI:10.1046/j.1365-2036.11.s1.14.x
16. Li L, Tan J, Liu L, et al. Association between H. pylori infection and health Outcomes: an umbrella review of systematic reviews and meta-analyses. BMJ Open. 2020;10(1):e031951. DOI:10.1136/bmjopen-2019-031951
17. Hunt R, Armstrong D, Katelaris P, et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol.  2017;51(6):467-78. DOI:10.1097/MCG.0000000000000854
18. Shaheen NJ, Falk GW, Iyer P, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am JGastroenterol. 2022;117(4):559-87. DOI:10.14309/ajg.0000000000001680
19. Mou WL, Feng MY, Hu LH. Eradication of Helicobacter Pylori Infections and GERD: A systematic review and meta-analysis. Turk J Gastroenterol. 2020;31(12):853-9. DOI:10.5152/tjg.2020.19699
20. Zhao Y, Li Y, Hu J, et al. The Effect of Helicobacter pylori Eradication in Patients with Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Studies. Dig Dis. 2020;38(4):261-8. DOI:10.1159/000504086
21. Wang XT, Zhang M, Chen CY, et al. Helicobacter pylori eradication and gastroesophageal reflux disease: a Meta-analysis. Zhonghua Nei Ke Za Zhi. 2016;55(9):710-6 (in Chinese).  DOI:10.3760/cma.j.issn.0578-1426.2016.09.011
22. Du YL, Duan RQ, Duan LP. Helicobacter pylori infection is associated with reduced risk of Barrett's esophagus: a meta-analysis and systematic review. BMC Gastroenterol. 2021;21(1):459. DOI:10.1186/s12876-021-02036-5
23. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-78. DOI:10.1016/S0140-6736(17)32448-0
24. Zhong Y, Zhang Z, Lin Y, et al. The Relationship Between Helicobacter pylori and Inflammatory Bowel Disease. Arch Iran Med. 2021;24(4):317-25. DOI:10.34172/aim.2021.44
25. Shirzad-Aski H, Sima B, Kienesberger S, et al. Association Between Helicobacter pylori Colonization and Inflammatory Bowel Disease. J Clin Gastroenterol. 2021;55(5):380-92. DOI:10.1097/MCG.0000000000001415
26. Wang L, Cao ZM, Zhang LL, et al. Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems. Front Immunol. 2022;13:833424. DOI:10.3389/fimmu.2022.833424
27. Yu Y, Zhu S, Li P, et al. Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. Cell Death Dis. 2018;9(10):961. DOI:10.1038/s41419-018-0982-2
28. Murad HA. Does Helicobacter pylori eradication therapy trigger or protect against Crohn's disease? Acta Gastroenterol Belg.  2016;79(3):349-54.
29. Lin KD, Chiu GF, Waljee AK, et al. Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019;17(10):1991-9. DOI:10.1016/j.cgh.2018.12.014
30. Chen C, Xun P, Tsinovoi C, et al. Accumulated evidence on Helicobacter pylori infection and the risk of asthma: A meta-analysis. Ann Allergy Asthma Immunol. 2017;119(2):137-45.e2.  DOI:10.1016/j.anai.2017.05.021
31. Zuo ZT, Ma Y, Sun Y, et al. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma. Int Arch Allergy Immunol.  2021;182(1):53-64. DOI:10.1159/000508330
32. Оганов Р.Г., Симаненков В.И., Бакулин И.Г., и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика.  2019;18(1):5-66 [Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66  (in Russian)]. DOI:10.15829/1728-8800-2019-1-5-66
33. Ширинский В.С., Ширинский И.В. Полиморбидность, старение иммунной системы и системное вялотекущее воспаление – вызов современной медицине. Медицинская иммунология. 2020;22(4):609-24 [Shirinsky VS, Shirinsky IV. Polymorbidity, ageing of immune system and low-grade systemic inflammation: a challenge for modern medicine. Medical Immunology (Russia). 2020;22(4):609-24  (in Russian)]. DOI:10.15789/1563-0625-PAO-2042
34. Shah SC, Tepler A, Chung CP, et al. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology. 2021;161(5):1443-59. DOI:10.1053/j.gastro.2021.07.043
35. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther. 2007;81(6):807-16. DOI:10.1038/sj.clpt.6100204
36. Дедов И.И., Тюльпаков А.Н., Чехонин В.П., и др. Персонализированная медицина: современное состояние и перспективы. Вестник Российской академии медицинских наук. 2012;67(12):4-12 [Dedov II, Tyul'pakov AI, Chekhonin VP, et al. Personalized medicine: state-of-the-art and prospects. Annals of the Russian Academy of Medical Sciences. 2012;67(12):4-12 (in Russian)]. DOI:10.15690/vramn.v67i12.474
37. Boffetta P, Collatuzzo G. Application of P4 (Predictive, Preventive, Personalized, Participatory) Approach to Occupational Medicine. Med Lav. 2022;113(1):e2022009. DOI:10.23749/mdl.v113i1.12622
38. Zhang YF, Shi J, Yu HP, et al. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus. World J Gastroenterol. 2012;18(27):3602-9. DOI:10.3748/wjg.v18.i27.3602
39. Matsuzaki J, Tsugawa H, Suzuki H. Precision Medicine Approaches to Prevent Gastric Cancer. Gut Liver. 2021;15(1):3-12.  DOI:10.5009/gnl19257
40. Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-50. DOI:10.1517/14728222.2015.1073261
41. de Brito BB, da Silva FAF, Soares AS, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019;25(37):5578-89. DOI:10.3748/wjg.v25.i37.5578
42. Matsumoto H, Shiotani A, Graham DY. Current and future treatment of Helicobacter pylori infections. Adv Exp Med Biol. 2019;1149:211-25. DOI:10.1007/5584_2019_367
43. Park JY, Forman D, Waskito LA, et al. Epidemiology of Helicobacter pylor and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins (Basel). 2018;10(4):163. DOI:10.3390/toxins10040163
44. Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol. 2014;20(21):6400-11.  DOI:10.3748/wjg.v20.i21.6400

________________________________________________

1. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273-5.
2. Sugano K, Tack J, Kuipers EJ, Graham DY. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67.  DOI:10.1136/gutjnl-2015-309252
3. Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI:10.1136/gutjnl-2016-312288
4. Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70  (in Russian). DOI:10.22416/1382-4376-2018-28-1-55-70
5. Park JY, Herrero R. Recent progress in gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2021;50-51:101733.  DOI:10.1016/j.bpg.2021.101733
6. Bordin DS, Voynovan IN, Embutnieks YuV, et al. European registry on Helicobacter pylori management  (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):12-8  (in Russian). DOI:10.26442/00403660.2020.02.000567
7. Reshetnyak VI, Burmistrov AI, Maev IV. Helicobacter pylori: Commensal, symbiont or pathogen? World J Gastroenterol. 2021;27(7):545-60. DOI:10.3748/wjg.v27.i7.545
8. Lansdorp-Vogelaar I, Meester RGS, Laszkowska M, et al. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol. 2021;50-51:101735. DOI:10.1016/j.bpg.2021.101735
9. Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 2021;22(6):729-41.  DOI:10.1080/14656566.2020.1845649
10. Tacconelli E, Carrara E, Savoldi A, et al. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-27.  DOI:10.1016/S1473-3099(17)30753-3
11. Moghadam MT, Chegini Z, Norouzi A, et al. Three-Decade Failure to the Eradication of Refractory Helicobacter pylori Infection and Recent Efforts to Eradicate the Infection. Curr Pharm Biotechnol. 2021;22(7):945-59. DOI:10.2174/1389201021666200807110849
12. Oh JH, Kwon JG, Jung HK, et al. Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil. 2020;26(1):29-50. DOI:10.5056/jnm19209
13. Gravina AG, Priadko K, Ciamarra P, et al. Extra-Gastric Manifestations of Helicobacter pylori Infection. J Clin Med. 2020;9(12):3887. DOI:10.3390/jcm9123887
14. Zuo ZT, Ma Y, Sun Y, et al. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma. Int Arch Allergy Immunol.  2021;182(1):53-64. DOI:10.1159/000508330
15. Marshall B. The future of Helicobacter pylori eradication: a personal perspective. Aliment Pharmacol Ther. 1997;11(Suppl. 1):109-15. DOI:10.1046/j.1365-2036.11.s1.14.x
16. Li L, Tan J, Liu L, et al. Association between H. pylori infection and health Outcomes: an umbrella review of systematic reviews and meta-analyses. BMJ Open. 2020;10(1):e031951. DOI:10.1136/bmjopen-2019-031951
17. Hunt R, Armstrong D, Katelaris P, et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol.  2017;51(6):467-78. DOI:10.1097/MCG.0000000000000854
18. Shaheen NJ, Falk GW, Iyer P, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am JGastroenterol. 2022;117(4):559-87. DOI:10.14309/ajg.0000000000001680
19. Mou WL, Feng MY, Hu LH. Eradication of Helicobacter Pylori Infections and GERD: A systematic review and meta-analysis. Turk J Gastroenterol. 2020;31(12):853-9. DOI:10.5152/tjg.2020.19699
20. Zhao Y, Li Y, Hu J, et al. The Effect of Helicobacter pylori Eradication in Patients with Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Studies. Dig Dis. 2020;38(4):261-8. DOI:10.1159/000504086
21. Wang XT, Zhang M, Chen CY, et al. Helicobacter pylori eradication and gastroesophageal reflux disease: a Meta-analysis. Zhonghua Nei Ke Za Zhi. 2016;55(9):710-6 (in Chinese).  DOI:10.3760/cma.j.issn.0578-1426.2016.09.011
22. Du YL, Duan RQ, Duan LP. Helicobacter pylori infection is associated with reduced risk of Barrett's esophagus: a meta-analysis and systematic review. BMC Gastroenterol. 2021;21(1):459. DOI:10.1186/s12876-021-02036-5
23. Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-78. DOI:10.1016/S0140-6736(17)32448-0
24. Zhong Y, Zhang Z, Lin Y, et al. The Relationship Between Helicobacter pylori and Inflammatory Bowel Disease. Arch Iran Med. 2021;24(4):317-25. DOI:10.34172/aim.2021.44
25. Shirzad-Aski H, Sima B, Kienesberger S, et al. Association Between Helicobacter pylori Colonization and Inflammatory Bowel Disease. J Clin Gastroenterol. 2021;55(5):380-92. DOI:10.1097/MCG.0000000000001415
26. Wang L, Cao ZM, Zhang LL, et al. Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems. Front Immunol. 2022;13:833424. DOI:10.3389/fimmu.2022.833424
27. Yu Y, Zhu S, Li P, et al. Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. Cell Death Dis. 2018;9(10):961. DOI:10.1038/s41419-018-0982-2
28. Murad HA. Does Helicobacter pylori eradication therapy trigger or protect against Crohn's disease? Acta Gastroenterol Belg.  2016;79(3):349-54.
29. Lin KD, Chiu GF, Waljee AK, et al. Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019;17(10):1991-9. DOI:10.1016/j.cgh.2018.12.014
30. Chen C, Xun P, Tsinovoi C, et al. Accumulated evidence on Helicobacter pylori infection and the risk of asthma: A meta-analysis. Ann Allergy Asthma Immunol. 2017;119(2):137-45.e2.  DOI:10.1016/j.anai.2017.05.021
31. Zuo ZT, Ma Y, Sun Y, et al. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma. Int Arch Allergy Immunol.  2021;182(1):53-64. DOI:10.1159/000508330
32. Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66  (in Russian). DOI:10.15829/1728-8800-2019-1-5-66
33. Shirinsky VS, Shirinsky IV. Polymorbidity, ageing of immune system and low-grade systemic inflammation: a challenge for modern medicine. Medical Immunology (Russia). 2020;22(4):609-24  (in Russian). DOI:10.15789/1563-0625-PAO-2042
34. Shah SC, Tepler A, Chung CP, et al. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology. 2021;161(5):1443-59. DOI:10.1053/j.gastro.2021.07.043
35. Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther. 2007;81(6):807-16. DOI:10.1038/sj.clpt.6100204
36. Dedov II, Tyul'pakov AI, Chekhonin VP, et al. Personalized medicine: state-of-the-art and prospects. Annals of the Russian Academy of Medical Sciences. 2012;67(12):4-12 (in Russian). DOI:10.15690/vramn.v67i12.474
37. Boffetta P, Collatuzzo G. Application of P4 (Predictive, Preventive, Personalized, Participatory) Approach to Occupational Medicine. Med Lav. 2022;113(1):e2022009. DOI:10.23749/mdl.v113i1.12622
38. Zhang YF, Shi J, Yu HP, et al. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus. World J Gastroenterol. 2012;18(27):3602-9. DOI:10.3748/wjg.v18.i27.3602
39. Matsuzaki J, Tsugawa H, Suzuki H. Precision Medicine Approaches to Prevent Gastric Cancer. Gut Liver. 2021;15(1):3-12.  DOI:10.5009/gnl19257
40. Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-50. DOI:10.1517/14728222.2015.1073261
41. de Brito BB, da Silva FAF, Soares AS, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019;25(37):5578-89. DOI:10.3748/wjg.v25.i37.5578
42. Matsumoto H, Shiotani A, Graham DY. Current and future treatment of Helicobacter pylori infections. Adv Exp Med Biol. 2019;1149:211-25. DOI:10.1007/5584_2019_367
43. Park JY, Forman D, Waskito LA, et al. Epidemiology of Helicobacter pylor and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins (Basel). 2018;10(4):163. DOI:10.3390/toxins10040163
44. Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol. 2014;20(21):6400-11.  DOI:10.3748/wjg.v20.i21.6400

В.И. Симаненков*1, С.А. Алексеенко2

1 ФГБОУ ВО «Северо-Западный государственный медицинский университет им. И.И. Мечникова» Минздрава России, Санкт-Петербург, Россия;
2 ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава России, Хабаровск, Россия
*visimanenkov@mail.ru

________________________________________________

Vladimir I. Simanenkov*1, Sergei A. Alekseenko2

1 Mechnikov North-Western State Medical University, Saint Petersburg, Russia;
2 The Far Eastern State Medical University, Khabarovsk, Russia
*visimanenkov@mail.ru